A quick word before we begin, because it matters. The patient in this article is not my patient. Let me be as clear as I can: this is not someone I am treating, this is not a patient in the United States, not in Florida, and not where I practice. This is a friend of a friend of a friend — a relatively young adult in India whose family reached out through a chain of people that eventually reached my inbox, hoping for a second set of eyes from an oncologist. I looked at what they shared, gave them my honest thoughts, and then asked for their permission to share the medical picture here — anonymously, with every identifying detail stripped out. They generously said yes. So think of this as two things at once: a direct answer to someone who sincerely asked me a question from thousands of miles away, and — because this disease is so much more common in his part of the world than in mine — a piece that might help the next person who goes looking for answers at 2 a.m. Nothing here is personal medical advice, and nothing here creates a doctor–patient relationship. It is education, offered in the spirit of one person trying to help another. Real decisions belong to him and the treating team who can examine him, hold his scans, and read his pathology in full.
Here is the situation, stripped of anything that could point back to him. A fit adult in his forties, no other major medical problems, presents with a cancer that involves roughly half of the right side of the liver. On imaging it looks like one of two closely related tumors: a bile duct cancer arising inside the liver (what we call intrahepatic cholangiocarcinoma, or iCCA), or a gallbladder cancer that has grown into the right lobe of the liver. Importantly, there is no sign that it has spread to distant organs. In a disease that so often shows up late, a young person with cancer that is still confined to one region is, relatively speaking, a favorable starting point. That single fact shapes everything that follows.
These tumors sit under one umbrella called biliary tract cancer. They are cousins — same neighborhood, different houses — and telling them apart matters more than you might think, because the exact diagnosis changes which modern drugs can help. I’ll come back to that.
WHY INDIA? THE GEOGRAPHY OF A DISEASE
If you practice oncology in the United States, gallbladder cancer is something you see occasionally. In parts of India, it is something you see often. India carries close to ten percent of the world’s gallbladder cancer burden — on the order of twenty-thousand-plus new cases every year — and it is by far the most common cancer of the biliary tract in the country.
What has always struck me is that this is not one disease spread evenly across one nation. There is a dramatic north-to-south gradient. Along the Gangetic belt — Uttar Pradesh, Bihar, Assam, West Bengal, and around Delhi — rates in women are among the highest recorded anywhere on earth. Travel to southern India and the disease nearly disappears. Women are affected about twice as often as men. And the hard part: most patients across India are diagnosed late, with something like six or seven in ten presenting at stage IV. That is exactly why a young patient caught while the disease is still local deserves an aggressive, hopeful, well-organized plan.
WHY DOES THIS HAPPEN? THE USUAL SUSPECTS
We don’t get to pick our rivers, our wells, or our family history — and in this disease, those things matter. The strongest and most consistent contributors in India are worth knowing, not to assign blame, but because they explain the map above:
- Gallstones. The dominant association. Only a small fraction of people with stones ever develop cancer, but large stones (over 3 cm) raise the risk meaningfully. It is a numbers game played out over decades of low-grade irritation.
- Chronic typhoid (Salmonella Typhi) carriage. One of the most robust links of all in typhoid-endemic regions — chronic carriers carry a markedly higher risk. A childhood infection that never fully cleared can smolder in the gallbladder for a lifetime.
- Contaminated water and heavy metals. Arsenic in groundwater — a real problem in parts of Bihar — and other agricultural and industrial exposures track closely with the geographic clustering.
- Aflatoxin. A toxin from mold on improperly stored crops, more common in parts of northern India and Nepal, is an emerging contributor.
- The rest of the list. Female sex, multiple pregnancies, tobacco, obesity and metabolic syndrome, and a family history of gallstones all add up. For bile duct cancer specifically, liver stones, chronic hepatitis, and fatty liver disease carry more weight.
Here is where modern oncology has genuinely changed. We no longer treat these cancers by name alone; we treat them by their molecular wiring. That is why one of the very first things I would want for this patient — alongside a good biopsy — is comprehensive genomic testing (NGS), ideally the kind that reads RNA so it can catch the gene fusions that ordinary panels miss.
This is also where the gallbladder-versus-bile-duct distinction earns its keep. Two of the most exciting targets — FGFR2 fusions and IDH1 mutations — are almost entirely a bile-duct (iCCA) story, each with its own approved pill. Meanwhile HER2, the same target we chase in breast and stomach cancer, is far more common in gallbladder cancer and is increasingly druggable. Roughly a third or more of biliary cancers carry at least one alteration we can act on. That is not a footnote; that is the reason NGS is non-negotiable here.
COULD THIS RUN IN THE FAMILY?
A cancer like this in someone in their forties raises a fair question: is there an inherited seed? For biliary cancers, up to roughly one in ten patients carries an inherited gene change that predisposed them — most often BRCA2 (yes, the same gene family from breast and ovarian cancer), and less often BRCA1, the Lynch syndrome genes, PALB2, ATM, and a few others.
This matters for two reasons. First, some of these findings open doors to specific therapies. Second, and just as important, it affects the patient’s family — siblings and children who might benefit from screening or peace of mind. For a young patient with no obvious liver risk factors, formal genetic counseling and germline testing is squarely the right move. He meets the threshold on age alone.
HOW WE TREAT IT TODAY: CHEMOTHERAPY THAT FINALLY HAS A PARTNER
For years, the backbone of treatment was two chemotherapy drugs, gemcitabine and cisplatin. They still are. What changed — and it is a real change — is that we now add immunotherapy (a checkpoint inhibitor such as durvalumab or pembrolizumab) on top. Two large international trials, TOPAZ-1 and KEYNOTE-966, both showed that adding immunotherapy helps patients live longer, without piling on side effects.
On paper the improvement in the average looks modest — a month or two. But averages hide the real prize. Look at the tail of the curve: the share of patients alive at three and four years roughly doubled. In this disease, that group — the long-term survivors — is exactly who we are fighting to expand. So chemoimmunotherapy is the front-line standard, and it is a sensible way to open treatment in this patient.
A few practical wrinkles I would keep in mind. If this behaves like a gallbladder cancer and the whole goal is maximum shrinkage to get to surgery, a more intensive three-drug chemotherapy combination (adding nab-paclitaxel) produced strikingly high response rates in an Indian trial — at the cost of more side effects, a trade a young, fit patient may well accept. And if the tumor turns out to be one of the biomarker-defined subtypes (say, MSI-high), the front-line plan can pivot to a matched therapy right away.
THE REAL GOAL: SHRINK IT, THEN REMOVE IT
Systemic therapy is how we start, but for a young patient with disease confined to the liver, it is not the destination. The destination is surgery. A cancer we can remove completely — with clean margins and enough healthy liver left behind — offers the best shot at long-term survival, and nothing else comes close. So the strategy I favor here is what we call a neoadjuvant, or conversion, approach: treat first, watch how the tumor responds, and use that response as information. Cancer that melts away and stays controlled tells us the biology is on our side and the patient is likely to benefit from an operation. Cancer that races ahead despite good treatment spares the patient a big surgery that wouldn’t have helped.
Indian and international series support this: down-staging chemotherapy can convert a meaningful fraction of locally advanced gallbladder cancers to a complete, margin-negative resection, with survival that pulls dramatically ahead of those who never get to surgery. It is worth noting honestly that giving chemotherapy before surgery in this setting is a reasonable, guideline-recognized option rather than a rigid rule — which is exactly why an experienced liver-surgery (HPB) team should be in the room from day one.
If the tumor behaves like a bile-duct cancer and stays stubbornly unresectable but liver-confined, there is another powerful tool: Y-90 radioembolization (TARE). Tiny radioactive beads are delivered straight into the tumor’s blood supply, concentrating radiation where it is needed and sparing the rest. Combined with chemotherapy, it can shrink tumors enough to convert some patients to surgery, or serve as durable local control. It is a genuine option for a right-lobe-dominant tumor — with the caveat that liver function and bilirubin have to be in the right range to use it safely.
IN PLAIN LANGUAGE — WHAT THIS ACTUALLY MEANS
If you are the friend reading this, or a family member, let me set the science aside and say it plainly.
The short version:
- You are young and otherwise healthy, and the cancer has not spread to distant parts of the body based on your PET scan. In this disease, that is a genuinely better starting point than most. Hold on to that.
- The first job is information: a good biopsy, deep genetic testing of the tumor, and a blood test for inherited risk. These tests decide which of several modern treatments fit you best — so they are worth the short wait.
- Treatment will most likely start with chemotherapy plus an immunotherapy drug. The aim is to shrink the tumor and prove the biology is on our side.
- The real goal is an operation to remove the cancer once it has shrunk, done by a specialized liver-surgery team. If surgery isn’t possible right away, targeted radiation beads (Y-90) can be another way to hit the tumor hard.
- Get care at a high-volume cancer center with a liver-surgery team and a tumor board — places that treat a lot of this disease get better results. This is a marathon with a plan, not a sprint. There is a clear, hopeful roadmap here.
To my friend across the world: I wish I could sit with you and your family over chai and walk through every scan. I can’t. But I can tell you that the plan above is sound, that your age and the localized nature of this are on your side, and that you should press for a liver-surgery team early. Ask your oncologist about clinical trials, too — in a disease evolving this fast, they are often a door to tomorrow’s treatment today. You are not walking this alone.
Dr. Sajeve Thomas is a distinguished medical professional and a compassionate guide in the field of oncology. With over a decade of dedicated experience as a board-certified medical oncologist/internal medicine specialist, Dr. Thomas has become a trusted expert in the treatment of melanoma, sarcoma, and gastrointestinal conditions. He brings a wealth of expertise to the complex and challenging world of oncology.
Disclosures:
Dr. Thomas serves as a speaker for BMS, Merck, Ipsen, Natera, Immunocore, Pfizer, Sun Pharma, SpringWorks. He also receives industry grants in support of numerous clinical trials.
Patient cases described in this post are composites and have been altered — including but not limited to diagnosis specifics, demographics, timeline, and clinical details — to protect patient privacy and confidentiality. No case represents an actual, identifiable patient, and any resemblance to a specific individual is coincidental. Clinical scenarios involving other providers have similarly been altered and are presented for educational purposes only, not as a representation of any specific person’s practice. This post is for general educational purposes and does not constitute medical advice; it should not be used to guide individual treatment decisions. This article is for education and general information only. It is written about an anonymized case, shared with permission, and it is not personal medical advice. The individual described is not a patient of the author, is not treated in the United States or at the author’s institution, and no doctor–patient relationship is created by reading this. Statistics and treatment options are summarized from the current oncology literature and evolve quickly; specific percentages are approximate. Any real medical decisions should be made with a qualified treating team that can evaluate the patient directly.
Leave a Reply